ME02149B - FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE - Google Patents
FORMULACIJE l METODE ZA LEČENJE AMILOIDOZEInfo
- Publication number
- ME02149B ME02149B MEP-2015-85A MEP8515A ME02149B ME 02149 B ME02149 B ME 02149B ME P8515 A MEP8515 A ME P8515A ME 02149 B ME02149 B ME 02149B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical composition
- use according
- approximately
- administered
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 238000009472 formulation Methods 0.000 title claims 3
- 206010002022 amyloidosis Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 6
- 229940109239 creatinine Drugs 0.000 claims 3
- 235000013305 food Nutrition 0.000 claims 3
- 235000012054 meals Nutrition 0.000 claims 3
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (8)
1.Farmaceutska kompozicija koja sadrži l ,3-propandisulfonsku kiselinu ili njenu farmaceutski prihvatljivu so za upotrebu u metodi za lečenje ili prevenciju bolesti vezanih za am i lo ide kod subjekta, gde je l ,3-propandisu lfonska kiselina ili njena farmaceutski prihvatljiva so administr irana u dozi od približno 1200 mg dva puta u toku dana za stopu klirensa kreatinina od >80 mL/min , u dozi od približno 800 mg dva puta u toku dana za stopu klirensa kreatinina od između približno 30 i 80 mL/min, ili u dozi od približno 400 mg dva puta u toku dana za stopu klirensa kreatinina od i zmeđu približno 20 i 30 mL/min.
2.Farmaceutska kompozicija za upotrebu prema patentnom zahtevu l , gde je farmaceutski prihvatljiva so dinatrij umova so 1,3- propandisulfonske kiseline.
3.Farmaceutska kompozicija za upotrebu prema patentnom zahtevu 1 ili 2, gde kompozicija dalje sadrži farmaceutski prihvatljivi nosač.
4.Farmaceutska kompozicija za upotrebu prema bilo kojem od patentnih za hteva od 1 do 3, gde je bolest vezana za amiloide AA amiloidoza.
5.Farmaceutska kompozicija za upot rebu prema bilo kojem od patentnih za hteva od l do 4, gde farmaceutska formulacija treba da bude administrirana bez hrane.
6.Farmaceutska kompozicija za upotrebu prema patentnom zahtevu 5, gde administracija bez hrane za posledicu ima porast u bioraspoloživosti od približno 25% ili v i še u poređenju sa administracijom sa hranom.
7.Farmaceutska kompozicija za upotrebu prema patentnom za htevu 5, gde je formulacija administrirana najmanje 1 ili 2 sata pre ili posle bilo kog obroka.
8.Farmaceutska kompozicija za upotrebu prema patentnom zahtevu 6, gde je formulacija adm inistrirana najmanje 1 sat pre obroka ili najmanje 2 sata posle obroka. 74
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67186605P | 2005-04-15 | 2005-04-15 | |
| EP06795492.5A EP1885350B9 (en) | 2005-04-15 | 2006-04-17 | Formulations and methods for treating amyloidosis |
| PCT/IB2006/002540 WO2007004072A2 (en) | 2005-04-15 | 2006-04-17 | Formulations and methods for treating amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02149B true ME02149B (me) | 2015-10-20 |
Family
ID=37499595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-85A ME02149B (me) | 2005-04-15 | 2006-04-17 | FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8178580B2 (me) |
| EP (2) | EP1885350B9 (me) |
| JP (2) | JP2008535906A (me) |
| KR (2) | KR20130133915A (me) |
| CN (2) | CN104873483A (me) |
| AU (1) | AU2006264498B2 (me) |
| BR (1) | BRPI0610592A2 (me) |
| CA (1) | CA2582556C (me) |
| DK (1) | DK1885350T3 (me) |
| EA (1) | EA018898B1 (me) |
| ES (1) | ES2534553T3 (me) |
| HK (1) | HK1214158A1 (me) |
| HR (1) | HRP20150320T1 (me) |
| HU (1) | HUE026044T2 (me) |
| IL (2) | IL186544A (me) |
| ME (1) | ME02149B (me) |
| MX (1) | MX2007012525A (me) |
| NO (1) | NO20075815L (me) |
| PL (1) | PL1885350T3 (me) |
| PT (1) | PT1885350E (me) |
| RS (1) | RS54050B1 (me) |
| SI (1) | SI1885350T1 (me) |
| TW (1) | TW200716088A (me) |
| WO (1) | WO2007004072A2 (me) |
| ZA (1) | ZA200709825B (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5994900A (en) * | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| US20070049638A1 (en) * | 2005-07-21 | 2007-03-01 | Neurochem (International) Limited | Polymorphic forms of 3-amino-1-propanesulfonic acid |
| MX2008008213A (es) * | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| KR101608445B1 (ko) | 2006-10-12 | 2016-04-01 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| EP2120905A1 (en) * | 2006-12-22 | 2009-11-25 | BELLUS Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| EA201290007A1 (ru) * | 2009-08-10 | 2013-01-30 | Беллус Хелс Инк. | Способы, соединения и композиции для доставки 1,3-пропандисульфокислоты |
| JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー，インコーポレイテッド | α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療 |
| CN109730988A (zh) * | 2014-04-30 | 2019-05-10 | 伊坎西奈山医学院 | 1，3-丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途 |
| WO2016023911A1 (en) * | 2014-08-11 | 2016-02-18 | Kiacta Sàrl | Use of 1,3-propanedisulfonic acid or salts thereof to prevent the onset of amyloidosis in select populations |
| CN116143672B (zh) * | 2023-02-28 | 2024-03-29 | 卫星化学股份有限公司 | 水溶性抗氧剂及其制备方法和应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2531468A (en) * | 1949-04-14 | 1950-11-28 | Eastman Kodak Co | Polyvinyl sulfonates and process for their preparation |
| DE1122064B (de) * | 1960-01-09 | 1962-01-18 | Basf Ag | Verfahren zur Einfuehrung von alyphatischen Kohlenwasserstoffresten in organische Verbindungen, die Hydroxylgruppen, tertiaere Aminogruppen, aromatische gebundene Sulfhydrylgruppen und bzw. oder aromatisch gebundene primaere oder sekundaere Aminogruppen enthalten |
| US3218352A (en) * | 1962-05-03 | 1965-11-16 | Abbott Lab | Homotaurine process |
| US3658966A (en) * | 1969-09-15 | 1972-04-25 | Kowa Co | Methods of treating hypertension |
| US3920833A (en) * | 1974-08-08 | 1975-11-18 | Stanley Drug Products Inc | Antifibrinolytic agents |
| FR2437834A1 (fr) | 1978-10-04 | 1980-04-30 | Lejeune Jerome | Compositions pharmaceutiques a base de l-serine ou de glycine |
| FR2457281A1 (fr) * | 1979-05-23 | 1980-12-19 | Meram Lab | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
| US4255448A (en) * | 1979-09-10 | 1981-03-10 | Wisconsin Alumni Research Foundation | Method for reducing epileptiform activity |
| US4448779A (en) * | 1981-07-16 | 1984-05-15 | Sanofi | Use of MS salt in geriatric medicine |
| JPS5879022A (ja) * | 1981-11-04 | 1983-05-12 | Bitamin Kenkyusho:Kk | 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤 |
| DE3390188C2 (de) | 1982-09-08 | 1987-07-23 | Mitsui Toatsu Chemicals | Verfahren zur herstellung einer Aminoalkylsulfonsäure |
| US4737353A (en) * | 1984-04-13 | 1988-04-12 | Union Carbide Corporation | Beryllium-aluminum-phosphorus-silicon-oxide molecular sieve compositions |
| IT1173990B (it) * | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale |
| JPH0733332B2 (ja) * | 1985-11-19 | 1995-04-12 | 富山化学工業株式会社 | 痴呆症状改善・治療剤 |
| JPH0786122B2 (ja) * | 1986-05-30 | 1995-09-20 | 日本ペイント株式会社 | 三次元架橋された微小樹脂粒子およびその製造法 |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| IT1205042B (it) * | 1987-05-28 | 1989-03-10 | Crinos Industria Farmaco | Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer |
| IT1211792B (it) | 1987-09-21 | 1989-11-03 | Sigma Tau Ind Farmaceuti | O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia |
| JPH01171638A (ja) | 1987-12-25 | 1989-07-06 | Kanegafuchi Chem Ind Co Ltd | 血清アミロイドａ蛋白用吸着体 |
| JP2587842B2 (ja) | 1987-12-09 | 1997-03-05 | 株式会社ニチレイ | 神経疾患治療・予防剤 |
| IT1212000B (it) | 1987-12-24 | 1989-11-08 | Sigma Tau Ind Farmaceuti | Fenilbenziliden-derivati dell'acido 3)amminopropansolfonico ad attivita' anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico della epilessia |
| US4968678A (en) | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
| ATE87918T1 (de) | 1988-02-19 | 1993-04-15 | Lilly Co Eli | Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren. |
| JPH0627072B2 (ja) | 1988-09-13 | 1994-04-13 | 呉羽化学工業株式会社 | アミノ安息香酸誘導体を有効成分とする生体内抗酸化機構調節剤 |
| JPH0667472B2 (ja) | 1988-11-28 | 1994-08-31 | 鐘淵化学工業株式会社 | 血清アミロイドｐ蛋白用吸着体 |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| JP2761048B2 (ja) | 1989-08-25 | 1998-06-04 | 三共株式会社 | 神経成長因子産生促進剤 |
| DE4004978A1 (de) | 1990-02-19 | 1991-08-22 | Nmi Naturwissenschaftl U Mediz | Praeventive therapie fuer morbus alzheimer |
| JP2780846B2 (ja) | 1990-05-01 | 1998-07-30 | インペリアル・ケミカル・インダストリーズ・ピーエルシー | 除草剤組成物 |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| DE4021066A1 (de) | 1990-07-03 | 1992-01-09 | Hoechst Ag | Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden |
| ES2100222T3 (es) * | 1990-07-19 | 1997-06-16 | Nippon Zoki Pharmaceutical Co | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. |
| JP2980749B2 (ja) | 1990-11-30 | 1999-11-22 | 協和醗酵工業株式会社 | フラン誘導体 |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
| GB9117716D0 (en) | 1991-08-16 | 1991-10-02 | Lynxvale Ltd | Gaba derivatives and their therapeutic application |
| DE59207848D1 (de) * | 1991-12-19 | 1997-02-20 | Ciba Geigy Ag | Aminosulfonsäurederivate und Verfahren zu ihrer Herstellung |
| US5318958A (en) * | 1992-05-29 | 1994-06-07 | Queen's University At Kingston | Amyloid precursor protein |
| US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| WO1994022437A2 (en) | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Method for treating amyloidosis |
| AU7376494A (en) | 1993-08-04 | 1995-02-28 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| AU703540B2 (en) * | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| CA2217322C (en) * | 1996-10-03 | 2005-01-04 | Coastside Bio Resources | Inhibition of complement pathway by sea cucumber fractions |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| US5869469A (en) * | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
| US6294583B1 (en) * | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| MXPA00007815A (es) * | 1998-02-11 | 2002-04-24 | Neurochem Inc | Metodo para modular la activacion de macrofagos. |
| US20020022657A1 (en) * | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
| US6329356B1 (en) * | 1998-04-10 | 2001-12-11 | Neurochem, Inc. | Phosphono-carboxylate compounds for treating amyloidosis |
| US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| AU1143200A (en) * | 1998-11-10 | 2000-05-29 | Neurochem, Inc. | Polymorphic forms of an amyloidosis inhibitor and methods of preparation |
| NZ543319A (en) | 1999-04-28 | 2007-06-29 | Neurochem Int Ltd | Compositions and methods for treating amyloidosis using sulphonate derivatives |
| US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| AU5994900A (en) * | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| WO2001085093A2 (en) * | 1999-12-23 | 2001-11-15 | Neurochem, Inc. | Compounds and methods for modulating cerebral amyloid angiopathy |
| US6376557B1 (en) * | 2000-03-16 | 2002-04-23 | Chanda Bhuwalka Zaveri | Methods for treating alopecia |
| US20020115717A1 (en) * | 2000-07-25 | 2002-08-22 | Francine Gervais | Amyloid targeting imaging agents and uses thereof |
| US7311893B2 (en) * | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
| US20020151506A1 (en) * | 2000-12-29 | 2002-10-17 | Castillo Gerardo M. | Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders |
| CA2725833A1 (en) * | 2001-01-12 | 2002-07-18 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
| WO2002073208A2 (en) * | 2001-03-13 | 2002-09-19 | Queen's University At Kingston | Anti-epileptogenic agents |
| US7501429B2 (en) * | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| WO2002096424A1 (en) * | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents |
| MXPA04001153A (es) * | 2001-08-31 | 2005-02-17 | Neurochem Int Ltd | Derivados de amidina para tratar la amiloidosis. |
| US20030077833A1 (en) * | 2001-09-07 | 2003-04-24 | Queen's University At Kingston | Diagnositc methods for determining susceptibility to convulsive conditions |
| WO2004058239A1 (en) * | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| MXPA05013607A (es) * | 2003-06-23 | 2006-04-06 | Neurochem Int Ltd | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050038000A1 (en) * | 2003-06-23 | 2005-02-17 | Xianqi Kong | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| US7253306B2 (en) * | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
| US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
| WO2006008661A2 (en) * | 2004-07-19 | 2006-01-26 | Neurochem (International) Limited | Diagnostic methods of multiple organ amyloidosis |
| BRPI0517790A (pt) * | 2004-11-12 | 2008-10-21 | Neurochem Int Ltd | métodos e composições fluoradas para tratar doenças relacionadas à amilóide |
| CA2586334A1 (en) * | 2004-11-16 | 2006-06-08 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| WO2006085149A2 (en) * | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
-
2006
- 2006-04-14 TW TW095113455A patent/TW200716088A/zh unknown
- 2006-04-17 CA CA2582556A patent/CA2582556C/en not_active Expired - Fee Related
- 2006-04-17 ZA ZA200709825A patent/ZA200709825B/xx unknown
- 2006-04-17 PT PT67954925T patent/PT1885350E/pt unknown
- 2006-04-17 KR KR1020137031182A patent/KR20130133915A/ko not_active Ceased
- 2006-04-17 AU AU2006264498A patent/AU2006264498B2/en not_active Ceased
- 2006-04-17 HU HUE06795492A patent/HUE026044T2/en unknown
- 2006-04-17 RS RS20150378A patent/RS54050B1/sr unknown
- 2006-04-17 ME MEP-2015-85A patent/ME02149B/me unknown
- 2006-04-17 HR HRP20150320TT patent/HRP20150320T1/hr unknown
- 2006-04-17 US US11/405,348 patent/US8178580B2/en not_active Expired - Fee Related
- 2006-04-17 BR BRPI0610592-0A patent/BRPI0610592A2/pt not_active IP Right Cessation
- 2006-04-17 CN CN201510104316.XA patent/CN104873483A/zh active Pending
- 2006-04-17 EP EP06795492.5A patent/EP1885350B9/en not_active Expired - Lifetime
- 2006-04-17 WO PCT/IB2006/002540 patent/WO2007004072A2/en not_active Ceased
- 2006-04-17 EP EP15157430.8A patent/EP2944308A1/en not_active Withdrawn
- 2006-04-17 DK DK06795492.5T patent/DK1885350T3/en active
- 2006-04-17 CN CNA2006800209754A patent/CN101528216A/zh active Pending
- 2006-04-17 KR KR1020077026646A patent/KR20080003895A/ko not_active Ceased
- 2006-04-17 EA EA200702237A patent/EA018898B1/ru not_active IP Right Cessation
- 2006-04-17 JP JP2008505996A patent/JP2008535906A/ja not_active Withdrawn
- 2006-04-17 MX MX2007012525A patent/MX2007012525A/es active IP Right Grant
- 2006-04-17 SI SI200631906T patent/SI1885350T1/sl unknown
- 2006-04-17 PL PL06795492T patent/PL1885350T3/pl unknown
- 2006-04-17 ES ES06795492.5T patent/ES2534553T3/es not_active Expired - Lifetime
-
2007
- 2007-10-10 IL IL186544A patent/IL186544A/en active IP Right Grant
- 2007-11-13 NO NO20075815A patent/NO20075815L/no not_active Application Discontinuation
-
2012
- 2012-05-15 US US13/472,368 patent/US20120270939A1/en not_active Abandoned
- 2012-12-12 JP JP2012271057A patent/JP5753152B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-23 US US13/901,432 patent/US20130296434A1/en not_active Abandoned
-
2014
- 2014-02-12 IL IL230935A patent/IL230935A0/en unknown
-
2016
- 2016-02-26 HK HK16102216.6A patent/HK1214158A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tuite et al. | Recent developments in the pharmacological treatment of Parkinson’s disease | |
| CA3105341A1 (en) | Methods of normalizing amino acid metabolism | |
| JP2002526407A5 (me) | ||
| JP2005528430A5 (me) | ||
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| US6979468B1 (en) | Oral composition and method for the treatment of inflammatory cutaneous disorders | |
| JPH10287560A (ja) | 医薬組成物 | |
| JPH07330584A (ja) | 疲労改善剤 | |
| US10946075B1 (en) | Radioprotection, radiomitigation and radiorecovery | |
| EP3086798A1 (en) | Formulations based on astragaloside iv or extracts containing it for the prevention and treatment of insomnia and jet-lag-related disorders | |
| EP0207011A2 (en) | Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| KR19980070878A (ko) | 새로운 진통제 조성물 | |
| JPH07330593A (ja) | 疲労改善剤 | |
| AU2020204558A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| JP6196847B2 (ja) | 防已含有組成物 | |
| CN104645334B (zh) | N‑乙酰半胱氨酸活性炭组合物及其制备方法和应用 | |
| JP2845988B2 (ja) | ベンフォチアミン製剤 | |
| US20080095865A1 (en) | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance | |
| US20250255926A1 (en) | Gingerol compositions and related methods | |
| WO2019094292A1 (en) | Compositions and methods of providing thyroid hormone of analogs thereof | |
| JP4896531B2 (ja) | 血中ＣｏＱ１０量を増加させる医薬組成物 | |
| EP1148882A1 (en) | Pharmaceutical combination of progesterone and folic acid | |
| JP2009507850A5 (me) | ||
| CN104540509A (zh) | 用于肝脏再生的药物组合物 |